SOMATROGON (Ngenla®)

Clinical Indication

Treatment of children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone.

Comments

In line with NICE TA863

Date of classification

July 2022

Red

Medicines which should be prescribed only in a specialist setting usually within a secondary or tertiary care service. NB: Some highly specialised RED medicines e.g. injectable treatments for cancer are not included on the LLR APC website list.